ArticleDiabetes, obesity & metabolism2020

Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.

Bruce A Perkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.